Harnessing the microbiome to transform lives

Harnessing the
microbiome
to transform lives

Corporate profile

Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs. Finch’s lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection (CDI) and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. Finch is also developing FIN-211 for children with autism spectrum disorder and significant gastrointestinal symptoms. Finch has a partnership with Takeda focused on the development of targeted microbiome therapeutics for inflammatory bowel disease.

Press releases

Finch Therapeutics to Present at the H.C. Wainwright Global Investment Conference
May 17, 2022
Finch Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
May 16, 2022
Finch Therapeutics to Host Corporate Update Conference Call and Webcast on May 16, 2022
May 9, 2022

Upcoming events

H.C. Wainwright Global Investment Conference

May 24, 2022 | 7:00 AM EDT
Latest presentation
Corporate Presentation – April 2022